1. Home
  2. CMMB vs PPBT Comparison

CMMB vs PPBT Comparison

Compare CMMB & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMMB
  • PPBT
  • Stock Information
  • Founded
  • CMMB 2004
  • PPBT 2010
  • Country
  • CMMB Israel
  • PPBT Israel
  • Employees
  • CMMB N/A
  • PPBT N/A
  • Industry
  • CMMB Biotechnology: Pharmaceutical Preparations
  • PPBT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CMMB Health Care
  • PPBT Health Care
  • Exchange
  • CMMB Nasdaq
  • PPBT Nasdaq
  • Market Cap
  • CMMB 15.8M
  • PPBT 9.2M
  • IPO Year
  • CMMB N/A
  • PPBT N/A
  • Fundamental
  • Price
  • CMMB $1.29
  • PPBT $4.10
  • Analyst Decision
  • CMMB Strong Buy
  • PPBT Strong Buy
  • Analyst Count
  • CMMB 3
  • PPBT 2
  • Target Price
  • CMMB $5.67
  • PPBT $126.50
  • AVG Volume (30 Days)
  • CMMB 209.5K
  • PPBT 50.9K
  • Earning Date
  • CMMB 11-07-2024
  • PPBT 11-19-2024
  • Dividend Yield
  • CMMB N/A
  • PPBT N/A
  • EPS Growth
  • CMMB N/A
  • PPBT N/A
  • EPS
  • CMMB N/A
  • PPBT N/A
  • Revenue
  • CMMB N/A
  • PPBT N/A
  • Revenue This Year
  • CMMB N/A
  • PPBT N/A
  • Revenue Next Year
  • CMMB N/A
  • PPBT N/A
  • P/E Ratio
  • CMMB N/A
  • PPBT N/A
  • Revenue Growth
  • CMMB N/A
  • PPBT N/A
  • 52 Week Low
  • CMMB $0.42
  • PPBT $3.76
  • 52 Week High
  • CMMB $2.55
  • PPBT $36.00
  • Technical
  • Relative Strength Index (RSI)
  • CMMB 36.04
  • PPBT 25.50
  • Support Level
  • CMMB $1.31
  • PPBT $3.76
  • Resistance Level
  • CMMB $1.59
  • PPBT $5.92
  • Average True Range (ATR)
  • CMMB 0.16
  • PPBT 0.64
  • MACD
  • CMMB -0.04
  • PPBT -0.17
  • Stochastic Oscillator
  • CMMB 12.24
  • PPBT 11.01

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

Share on Social Networks: